Receptor T Cells in a Mouse Model Second-Generation Chimeric Antigen in Autotoxicity Driven by CD19-Specific Differential Role of Th1 and Th2 Cytokines

,

[1]  P. Zou,et al.  Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis. , 2013, Gene.

[2]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[3]  D. Teachey,et al.  CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc). , 2012 .

[4]  S. Rosenberg,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[5]  D. Gilham,et al.  Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells , 2011, Gene Therapy.

[6]  Adrian P Gee,et al.  Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.

[7]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[8]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[9]  A. Bondanza,et al.  Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T Lymphocytes , 2011, Journal of Cancer.

[10]  Hao Liu,et al.  CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.

[11]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[12]  S. Rosenberg,et al.  Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. , 2010, Blood.

[13]  H. Heslop,et al.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety , 2010, Leukemia.

[14]  M. Sadelain,et al.  Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  H. Abken,et al.  Building better chimeric antigen receptors for adoptive T cell therapy. , 2010, Current gene therapy.

[16]  Z. Eshhar.  Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic. , 2010, Current opinion in molecular therapeutics.

[17]  S. Dovedi,et al.  Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells , 2010, The Journal of Immunology.

[18]  M. Brenner,et al.  Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". , 2009, Human gene therapy.

[19]  W. Wilson,et al.  Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor , 2009, Journal of immunotherapy.

[20]  Richard P. Junghans,et al.  Second-Generation Anti–Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity In vivo: A Preclinical Evaluation , 2008, Clinical Cancer Research.

[21]  G. Dedoussis,et al.  TH1 and TH2 cell polarization increases with aging and is modulated by zinc supplementation , 2008, Experimental Gerontology.

[22]  P. Rodriguez,et al.  Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives , 2008, Immunological reviews.

[23]  David D. Smith,et al.  CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.

[24]  M. Brenner,et al.  Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells , 2006, Leukemia.

[25]  E. Cevenini,et al.  Age-dependent modifications of Type 1 and Type 2 cytokines within virgin and memory CD4+ T cells in humans , 2006, Mechanisms of Ageing and Development.

[26]  Peter Boyle,et al.  Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. , 2006, Blood.

[27]  M. Takemura,et al.  Age‐related changes in intracellular cytokine profiles and Th2 dominance in allergic children , 2006, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[28]  J. Ochoa,et al.  CD11b+/Gr-1+ Myeloid Suppressor Cells Cause T Cell Dysfunction after Traumatic Stress1 , 2006, The Journal of Immunology.

[29]  J. Ochoa,et al.  Arginine availability, arginase, and the immune response , 2003, Current opinion in clinical nutrition and metabolic care.

[30]  C. von Kalle,et al.  Polyclonal long-term repopulating stem cell clones in a primate model. , 2002, Blood.

[31]  R. Guest,et al.  Primary Polyclonal Human T Lymphocytes Targeted to Carcino-Embryonic Antigens and Neural Cell Adhesion Molecule Tumor Antigens by CD3ζ-Based Chimeric Immune Receptors , 2002, Journal of immunotherapy.

[32]  Y. Ikeda,et al.  T-helper (Th)1/Th2 imbalance in patients with previously untreated B-cell diffuse large cell lymphoma , 2001, Cancer Immunology, Immunotherapy.

[33]  E. Pearce,et al.  Differential Regulation of Nitric Oxide Synthase-2 and Arginase-1 by Type 1/Type 2 Cytokines In Vivo: Granulomatous Pathology Is Shaped by the Pattern of l-Arginine Metabolism1 , 2001, The Journal of Immunology.

[34]  B. Seliger,et al.  T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. , 2001, Cancer research.

[35]  A. Prasad.  Effects of zinc deficiency on Th1 and Th2 cytokine shifts. , 2000, The Journal of infectious diseases.

[36]  E. Catena,et al.  Th1/Th2 lymphocyte polarization in asthma , 2000, Allergy.

[37]  P. Perrin,et al.  The schistosome granuloma: characterization of lymphocyte migration, activation, and cytokine production. , 1998, Journal of immunology.

[38]  A. Lawson,et al.  Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. , 1998, Journal of immunology.

[39]  M. Sadelain,et al.  Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes , 1998, The Journal of experimental medicine.

[40]  M. Kaplan,et al.  Th2 cells are required for the Schistosoma mansoni egg-induced granulomatous response. , 1998, Journal of immunology.

[41]  J. Rygaard,et al.  Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[42]  P. Kearney,et al.  Effects of L-arginine on the proliferation of T lymphocyte subpopulations. , 2001, JPEN. Journal of parenteral and enteral nutrition.

[43]  R. Locksley,et al.  The regulation of immunity to Leishmania major. , 1995, Annual review of immunology.

[44]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.